Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

These Athletes Weren't Doping. Their Genes Made It Look Like They Did.

2.

High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer

3.

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

4.

Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma

5.

Researchers discover cellular 'doorway' exploited by cancer-causing virus


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot